Nicholas Franks
Nicholas Peter Franks FRS FRSB (born 14 October 1949) has been Professor of Biophysics and Anaesthetics at Imperial College London since 1993.[1] His research focuses on how general anaesthetics act at the cell and molecular levels as well as with neuronal networks.[2] Franks holds patents on use of xenon gas as a neuroprotectant [3] and has published research on the use of the anesthetic properties of xenon.[4]
He was educated at Mill Hill School and King's College London (BSc 1972; PhD 1975).[5] He was a lecturer in biophysics at Imperial College London from 1977 to 1989 and a reader in biophysics from 1989 to 1993.
Awards and honours
Along with being made a Fellow of the Royal Society in 2011, Franks is also a Fellow of the Royal Society of Biology. He was a Distinguished Lecturer in Neuroscience at the University of Toronto and Stuart Cullen Lecture, University of California San Francisco.
References
- ^ "Professor Nick Franks, FRS". Imperial College London. Retrieved 15 March 2016.
- ^ Franks, Nicholas (2014). "The role of K2P channels in anaesthesia and sleep". European Journal of Physiology. 467 (5): 907–916. doi:10.1007/s00424-014-1654-4. PMC 4428837. PMID 25482669.
- ^ Dickinson, R (2007). "Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor by the anesthetics xenon and isoflurane: evidence from molecular modeling and electrophysiology". Anesthesiology. 107 (5): 756–67. doi:10.1097/01.anes.0000287061.77674.71. PMID 18073551.
- ^ Franks, Nicholas (1998). "How does xenon produce anaesthesia?". Nature. 396 (6709): 324. Bibcode:1998Natur.396..324F. doi:10.1038/24525. PMID 9845069. S2CID 4415640.
- ^ "FRANKS, Prof. Nicholas Peter", Who's Who 2016, A & C Black, 2016
External links
- Neuroprotexeon Scientific Advisory Board
- "Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial", The Lancet Neurology, volume 15, issue 2, p 145-153, 1 February 2016
- "Xenon Improves Neurologic Outcome and Reduces Secondary Injury Following Trauma in an In Vivo Model of Traumatic Brain Injury", Critical Care Medicine, January 2015, volume 43, issue 1, p 149-158, doi: 10.1097/CCM.0000000000000624